Fetuin-A is a hepatic secretory protein and a novel risk factor for diabetes. However, it remains unclear whether the association between high levels of fetuin-A and diabetes can be attributed to nonalcoholic fatty liver disease. We conducted a case-cohort study among 1,957 subcohort members and 455 incident diabetes cases in the Multi-Ethnic Study of Atherosclerosis, a multicenter US study of Caucasian, African-American, Hispanic, and Chinese-American adults aged 45-84 years. Serum fetuin-A and computed tomography-determined liver fat content were measured from samples collected at baseline (2000)(2001)(2002). In multivariable Cox proportional hazards models with follow-up through 2012, a higher fetuin-A level was associated with a higher risk of diabetes, with a stronger association among women (for top quartile vs. bottom, hazard ratio (HR) = 3.36, 95% confidence interval (CI): 2.08, 5.44) than among men (HR = 1.47, 95% CI: 0.93, 2.35) (P-heterogeneity = 0.001). Adjustment for liver fat content attenuated these associations slightly (women: HR = 2.61, 95% CI: 1.59, 4.26; men: HR = 1.32, 95% CI: 0.84, 2.08). In this study, we observed a particularly strong association of fetuin-A with diabetes risk in women that could not be explained by liver fat.
In the United States, diabetes mellitus currently affects 12.3% of the population aged 20 years or older, with the prevalence being even higher among most racial/ethnic minority groups (1) . The identification of novel factors involved in the pathophysiology of diabetes could enhance our understanding of mechanisms responsible for interindividual variation in susceptibility to diabetes and allow for targeted prevention strategies. One novel factor of interest is fetuin-A, a hepatic secretory protein found in high concentrations in human serum (2) . In vitro studies demonstrate that fetuin-A can noncompetitively and reversibly bind the insulin receptor tyrosine kinase in muscle and fat, inhibiting downstream internal signaling cascades and resulting in peripheral insulin resistance (3) . An association between higher circulating fetuin-A concentrations and incident diabetes has consistently been reported in several prospective epidemiologic studies (4) (5) (6) (7) (8) . However, potential mechanisms relating fetuin-A to diabetes risk remain uncertain.
We (9) and others (7, 8) have hypothesized that nonalcoholic fatty liver disease (NAFLD), a highly prevalent condition (10) associated with both insulin resistance (11) and higher fetuin-A concentrations (12) , may be involved in the association between fetuin-A and diabetes. Because it is not known whether fetuin-A influences liver fat content or the accumulation of liver fat might lead to higher fetuin-A levels (9) , it is unclear whether fetuin-A might serve as a confounder or mediator or whether associations might vary by liver fat content. Prior studies have been limited to serum liver enzymes as markers of NAFLD and have not found that NAFLD accounts for (4, 7, 8) or modifies (8) associations between fetuin-A and incident diabetes. However, to our knowledge, no study has used imaging modalities to assess NAFLD directly in addressing this question. Herein, we measured serum fetuin-A in a case-cohort study sampled within the Multi-Ethnic Study of Atherosclerosis (MESA), which concurrently collected information on liver fat content from all study participants via cardiac computed tomography (CT) imaging. Our objective was to investigate the relationship between fetuin-A and incident diabetes while accounting for liver fat content and other relevant biomarkers in an ethnically diverse population. In addition, we synthesized the epidemiologic evidence on fetuin-A and diabetes obtained to date from our study and prior prospective studies in a random-effects meta-analysis.
METHODS

Study population
Participants were enrolled in MESA, a multicenter prospective cohort study designed to evaluate the progression of subclinical and clinical cardiovascular disease (13) . Informed consent was obtained from all study participants, and the institutional review board at each study site approved the study protocol.
In 2009, participants were selected for fetuin-A measurement using a case-cohort study design, as detailed in Web Figure 1 (available at http://aje.oxfordjournals.org/). From our original sample of 2,774 subcohort members and 456 cases that developed through 2012 (227 within the subcohort), we excluded persons with insufficient serum for fetuin-A measurement (n = 241), those with prevalent diabetes (n = 298), those missing information on diabetes at baseline (n = 2) or in all subsequent examinations (n = 2), those without liver images for evaluation of liver fat (n = 64), heavy alcohol drinkers (men reporting current or past consumption of >14 drinks/week and women reporting >7 drinks/week) as per the definition of NAFLD (14) (n = 221), and those missing covariate information (n = 28). Our final sample included 1,957 subcohort members and 455 cases, 265 of whom also belonged to the subcohort (185 from the original case-cohort selection in 2009 and 80 from continued follow-up through 2012). Thus, the final sample size for this analysis was 2,147 individuals.
Fetuin-A measurements
As described previously (15) , stored frozen venous serum samples (−70°C) from the baseline visit (2000) (2001) (2002) were thawed in 2009, and fetuin-A was measured at the Clinical Chemistry Laboratory at the University of Maryland using a 2-site "sandwich" enzyme-linked immunosorbent assay (ELISA) kit (Epitope Diagnostics, San Diego, California). Case samples were aliquoted, shipped, and measured under the same conditions as subcohort samples. Case and subcohort samples were evenly dispersed on each assay plate, and all laboratory technicians were blinded to case status. The average of 2 fetuin-A measurements from each specimen was used in analyses. Intraassay coefficients of variation from fetuin-A measurements were 2.1%-3.4%, and interassay coefficients of variation were 5.7%-6.8%.
Incident diabetes
Diabetes was assessed at each examination and defined according to the American Diabetic Association criteria as fasting plasma glucose concentration ≥7.0 mmol/L (≥126 mg/dL) or use of insulin or oral hypoglycemic medication (16) . For participants missing data on diabetes status at some followup examinations (n = 85), determination of case status was based on examinations with available data, and time-toevent was set to the first examination at which diabetes was identified.
NAFLD and other covariates
Information on NAFLD and all other covariates was obtained at the baseline examination concurrent with fetuin-A measurements. Cardiac CT scans covering the liver and spleen were used for the determination of liver fat content, as described previously (14) . Age, sex, race/ethnicity, education, income, smoking, menopausal status, postmenopausal hormone (PMH) use, alcohol consumption, and physical activity were ascertained with standardized questionnaires. High-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, C-reactive protein, cystatin C, and insulin were measured from fasting blood samples. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as insulin (mU/L) × (glucose (mg/dL) × 0.055)/22.5. Resting systolic blood pressure and anthropometric measurements were obtained by trained personnel. Further details on the measurement of liver fat and calculation of clinical variables are available in Web Appendix 1.
Statistical analyses
The distribution of baseline characteristics was examined among cases and subcohort members. The association of fetuin-A concentrations with incident diabetes was evaluated using Cox proportional hazards regression, with Kalbfleisch and Lawless weights and the robust variance estimator applied to account for the case-cohort design (17) . Personyears for each participant were calculated from the midpoint of the baseline examination period (August 7, 2001) to the midpoint of the examination period in which the participant was determined to have diabetes or was censored due to loss to follow-up, death, or the end of follow-up at examination 5 (in 2012). The exact method (18) was used for handling these tied event and censoring times, and nonproportionality by age was resolved by including age-specific hazard functions.
Because we observed no deviation from linearity using restricted cubic splines, we evaluated hazard ratios per standard deviation (SD) increment in fetuin-A concentration (0.10 g/L), with the SD based on the distribution of fetuin-A levels in the total study population. Because associations differed by sex in initial analyses, we conducted all further analyses separately in males and females. No differences in the association were observed according to other diabetes risk factors (age (<65 years, ≥65 years), race/ethnicity (Caucasian, African-American, Hispanic, Chinese-American), or menopausal status/PMH use (premenopausal, postmenopausal with current use, or postmenopausal with non-current use)). Associations were modeled across sex-specific quartiles as well as linearly. Initial models were stratified by age (in years) and adjusted for race/ethnicity. The multivariable model additionally included other important risk factors for diabetes: body mass index (weight (kg)/height (m) 2 ), smoking status, alcohol consumption, income, and (for women only) menopausal status/PMH use.
To evaluate whether NAFLD might account for the association between fetuin-A and diabetes, we additionally adjusted for liver density (Hounsfield Units (HU)), with liver density treated continuously to optimize power. We also examined whether associations between fetuin-A (treated as a continuous variable) and diabetes varied by the presence (<51 HU) or absence (≥51 HU) of NAFLD. We examined the influence of other clinical variables when they were added individually and simultaneously to the multivariable-adjusted model: waist circumference, systolic blood pressure, blood lipid concentrations (high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides), C-reactive protein level, estimated glomerular filtration rate, and HOMA-IR. To further evaluate whether fetuin-A might be associated with diabetes through the promotion of insulin resistance, we compared least-squares mean HOMA-IR values from examinations 1 and 5 (the only examinations with available measurements) across fetuin-A quartiles using mixed models.
We pooled our multivariable-adjusted continuous estimates with those from prior prospective studies of fetuin-A and diabetes (4, 6-8) in a random-effects meta-analysis. All estimates were made per 0.10-g/L increase in fetuin-A concentration, which represented approximately 1 SD in all studies. To further examine variation in the association by sex, we performed meta-regression to investigate sex as a source of heterogeneity across studies. A comparison of study characteristics in MESA and prior studies, including details of fetuin-A and liver fat measurements, is presented in Web Table 1 . All analyses were performed using SAS software, version 9.4 (SAS Institute, Inc., Cary, North Carolina), except for the meta-analyses, which were performed using STATA, version 12.1 (StataCorp LP, College Station, Texas). All reported P values are 2-sided.
RESULTS
Participant characteristics
The prevalence of NAFLD was 15% in both males and females, but NAFLD prevalence varied substantially by race/ethnicity (Caucasians: 14%, African Americans: 8%, Hispanics: 25%, Chinese Americans: 17%). Baseline characteristics were generally similar for males and females (Tables 1 and  2 ). Compared with subcohort members, participants who subsequently developed diabetes were more than twice as likely to have NAFLD, were less likely to be Caucasian, were less educated, had a lower income, and had a higher body mass index and greater waist circumference.
Fetuin-A and liver fat content
Fetuin-A concentrations were higher in women with greater liver fat content (P-linearity < 0.0001) ( Figure 1A ). Among men, a J-shaped association between fetuin-A and liver fat was present (P-linearity < 0.0001; P-quadratic = 0.08), with the lowest concentrations being observed in the second quartile of liver fat ( Figure 1B ).
Associations between fetuin-A and incident diabetes
Associations between fetuin-A and incident diabetes were stronger among women than among men (P-heterogeneity = 0.001); we observed similarly divergent associations in longitudinal analyses of HOMA-IR (Web Figure 2) . In models adjusting for age and race/ethnicity, women in the top quartile of fetuin-A were at an approximately 3-fold higher risk of incident diabetes than those in the bottom quartile (Table 3) . Each SD (0.10 g/L) increment in fetuin-A among women was associated with a nearly 50% higher risk of diabetes. This association was similar in models that additionally adjusted for body mass index, menopausal status/ PMH use, smoking, alcohol consumption, and income (per SD increment in fetuin-A, hazard ratio (HR) = 1.51, 95% confidence interval (CI): 1.32, 1.74). Further adjustment for liver fat content slightly attenuated associations (per SD increment, HR = 1.37, 95% CI: 1.19, 1.59). As expected, adjustment for HOMA-IR attenuated estimates more substantially (HR = 1.28, 95% CI: 1.11, 1.48); no other clinical variables influenced the association among females when added individually to the main multivariable models. A 21% higher risk per SD remained after adjustment for liver fat, HOMA-IR, and all other clinical variables simultaneously (95% CI: 1.04, 1.41) (Figure 2 ).
Fetuin-A was also positively associated with incident diabetes among men, but the association was more modest (Table 3 ). In models that adjusted for body mass index, smoking, alcohol consumption, and income, men in the top quartile of fetuin-A were at 47% higher risk of incident diabetes than were men in the bottom quartile (95% CI: 0.93, 2.35), and each SD increment in fetuin-A was associated with a 12% higher risk of diabetes (95% CI: 0.94, 1.32). Associations were minimally attenuated after additional adjustment for liver fat (per SD increment, HR = 1.06, 95% CI: 0.90, 1.24) and were no longer present with adjustment for HOMA-IR (per SD increment, HR = 0.97, 95% CI: 0.83, 1.14) (Figure 2 ). When liver density was used to define the presence of NAFLD (<51 HU), multivariable associations between fetuin-A and incident diabetes did not differ by NAFLD presence in either men (P-heterogeneity = 0.99) or women (P-heterogeneity = 0.91).
In meta-analyses combining our results with those from prior studies (4, (6) (7) (8) , each 0.10-g/L increment in fetuin-A was associated with a 22% higher risk of diabetes (95% CI: 1.07, 1.40). While positive associations were reported in all studies, there was significant heterogeneity of estimates across studies (P-heterogeneity < 0.0001) (Figure 3 ). We included our findings and sex-specific results from 2 additional reports (4, 8) in a meta-regression analysis examining whether sex was associated with the effect size. The regression coefficient tended to be greater in women than in men (P = 0.18).
DISCUSSION
In this multiethnic cohort of middle-aged to older adults without clinically evident cardiovascular disease at study inception, higher serum fetuin-A concentrations were strongly associated with risk of incident diabetes among females. Similar but more modest associations were observed in men. Adjustment for CT-determined liver fat content minimally attenuated these associations. Overall, these data suggest that the association of fetuin-A with diabetes is independent of NAFLD.
Several lines of evidence suggest that NAFLD may be involved in the relationship between fetuin-A and incident diabetes. Although the fetuin-A regulatory pathways are incompletely understood, hyperglycemia (via extracellular signal-regulated kinases 1 and 2 (ERK-1/2)) and inflammation (via nuclear factor κB), conditions related to the pathogenesis of both NAFLD and diabetes, have been shown to induce hepatic fetuin-A production. NAFLD often occurs in conjunction with diabetes and the metabolic syndrome (11) , and several prospective studies have found associations between NAFLD and incident diabetes (19, 20) . In addition, higher fetuin-A concentrations have been observed among patients with greater liver fat content (12), consistent with findings from our analyses.
Our data instead indicate that NAFLD is unlikely to play a complete role in the association between fetuin-A and diabetes, as accounting for NAFLD using CT-determined liver fat content had little influence on the observed association. Similarly, previous epidemiologic studies (4, 7, 8) did not find any change in the association after adjustment for liver enzyme levels (alanine transaminase and γ-glutamyltranspeptidase) as surrogate measures of liver fat (21) . However, these enzymes are considered weak proxies for liver fat (22) and were minimally correlated with fetuin-A in prior studies (Nurses' Health Study (8) : for alanine transaminase, ρ = 0.03 and for γ-glutamyltranspeptidase, ρ = 0.003; European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam (7): for γ-glutamyltranspeptidase, ρ = 0.06). Our use of CT imaging, a more reliable method for the diagnosis of liver fat (22) , and our higher correlations between fetuin-A and CT-determined liver fat content (ρ = 0.20 in women and ρ = 0.12 in men) more strongly support an association between fetuin-A and diabetes independent of NAFLD. We also observed similar associations between fetuin-A and diabetes among persons with and without NAFLD, indicating that fetuin-A and NAFLD do not act synergistically to increase the risk of diabetes.
The sex-specific associations that we observed in MESA corroborate findings from our smaller prospective cohort study in the Rancho Bernardo cohort (4), which was drawn from a population of primarily Caucasian, middle-to upperclass older US adults. Despite demographic differences between the two cohorts, the magnitudes of associations in both females (per SD increment in fetuin-A, HR = 1.64, 95% CI: 1.16, 2.32) and males (per SD increment in fetuin-A, HR = 1.12, 95% CI: 0.81, 1.53) in the Rancho Bernardo Study were remarkably similar to those in MESA (SD = 0.10 g/L in both cohorts). Positive associations between fetuin-A and incident diabetes have been observed in several other cohorts (5) (6) (7) (8) . However, in the 3 additional studies that included both males and females, investigators did not observe significant differences in the association by sex (5) (6) (7) . This may be due to variation in the distributions of diabetes risk factors by sex across study populations and limited case numbers in some of these studies. Regardless, because marked sex differences have now been observed ; continuous), smoking status (never, former, or current smoker), alcohol drinking status (never, former, or current drinker), current alcohol consumption (number of drinks/week), and income (<$25,000, $25,000-$49,999, $50,000-$74,999, or ≥$75,000 per year). For women, MV models additionally adjusted for menopausal status/postmenopausal hormone use (premenopausal, postmenopausal with current use, or postmenopausal with non-current use).
c Liver fat content was measured in continuous Hounsfield Units (HU).
in 2 independent cohort studies, future studies evaluating associations of fetuin-A with diabetes and other outcomes should include rigorous evaluation of potential sex differences. Sex differences in diabetes pathophysiology, although not fully understood, may account for the stronger associations we observed in women. It has been demonstrated in a number of populations that men are more likely to have impaired fasting glucose, whereas women more commonly have impaired glucose tolerance (23, 24) . High fetuin-A levels appear to be particularly strongly associated with impaired glucose tolerance (4, 25) , and thus fetuin-A may be more closely related to diabetogenic pathways that are especially important in women. In addition, the higher fasting glucose concentration among males in MESA may have made them more likely to progress to diabetes over the follow-up period even in the absence of high fetuin-A; thus, the relative importance of fetuin-A as a risk factor for diabetes may be less evident among males in our study population. We also considered the possibility that the observed sex differences might be explained by higher circulating estrogen levels among women, as endogenous estrogen concentrations have been associated with incident diabetes among postmenopausal women in MESA (26) , and fetuin-A concentrations in our study population were higher among premenopausal women (mean = 0.50 (SD, 0.09) g/L) and postmenopausal PMH users (mean = 0.51 (SD, 0.12) g/L), subgroups with higher endogenous estrogen concentrations (27) , in comparison with men (mean = 0.47 (SD, 0.10) g/L). The association between hormone use and higher circulating fetuin-A level has been a consistent finding in prior studies (4, 28) . However, our results were similar in analyses restricted to women with and without PMH use at baseline, although numbers were modest. We also examined whether estrogen might confound estimates among women, but adjustment for menopausal status and PMH use had little influence on the association. Thus, sex differences in the association of fetuin-A with diabetes appear not to be explained entirely by differences in estrogen status.
Additional investigations are needed to understand whether the relationship between fetuin-A and diabetes is causal. A role for fetuin-A in the development of diabetes has been suggested based on the location of the fetuin-A gene (α 2 -Heremans-Schmid glycoprotein (AHSG)) on chromosome arm 3q27, a diabetes susceptibility locus (29) . Moreover, fetuin-A knockout mice are highly insulin-sensitive (30) , and conversely, treating wild-type mice with exogenous fetuin-A acutely worsens insulin resistance (31) . The strong association among females that persisted after adjustment for liver fat and other metabolic factors in our study strengthens evidence for a causal relationship between fetuin-A and diabetes. The density of estimates with adjustment for HOMA-IR and the elevation in HOMA-IR at higher fetuin-A levels in both sexes further suggests that this relationship may manifest via inhibition of insulin signaling pathways. However, the potential causal nature of this association was recently called into question by the results of a Mendelian randomization analysis in the Cardiovascular Health Study population (an elderly cohort), in which Jensen et al. (32) found no association between genetic variants strongly predictive of fetuin-A concentrations and incident diabetes. Although this approach is expected to be free from confounding and other biases (33) , an association may have been missed due to the small sample size or the limited age distribution of participants in the Cardiovascular Health Study. Experimental evidence demonstrating an improvement in insulin sensitivity with selective reduction of fetuin-A concentrations will ultimately be required to establish causality.
In addition to our more robust measure of liver fat, our study had a number of important strengths that allowed us to expand upon previous findings. In contrast to prior studies (listed in Web Table 1 ), which were carried out in predominantly Caucasian populations, our analyses included substantial numbers of participants from 4 different racial/ ethnic groups. In addition, the relatively large sample size and inclusion of both sexes allowed us to conduct detailed sex-specific analyses, and the broad age range permits generalization of our results to both middle-aged and older populations. Rather than relying on self-reports for case ascertainment as in the EPIC-Potsdam Study (7) and the Nurses' Health Study (8) , all participants in MESA were screened for diabetes at each follow-up examination, reducing the possibility of bias due to underdiagnosis of incident diabetes. The somewhat higher diabetes incidence rates in MESA as compared with rates based on self-reported data from the National Health Interview Survey (34) support the completeness of our case ascertainment methods. Although the EPIC-Potsdam Study is the largest prospective study of fetuin-A and diabetes to have been carried out to date, it was the only study to use primarily nonfasting fetuin-A samples, which the authors acknowledged may have weakened their estimates (7). Moreover, EPIC-Potsdam was the only study to use the BioVendor ELISA (BioVendor, Inc., Modreci, Czech Republic), which has been shown to differ from the Epitope Diagnostics ELISA (35) used in all other studies in its specificity to fetuin-A.
Our study also had important limitations. As in prior studies, we had only baseline measures of fetuin-A and liver fat content, precluding our ability to fully address the directionality of the relationship between fetuin-A and NAFLD. The availability of fetuin-A measurements at a (5) were not included in the meta-analysis because continuous estimates were only reported per doubling of fetuin-A levels (hazard ratio = 1.57, 95% CI: 0.99, 2.49). Bars, 95% confidence intervals (CIs).
single time point may have weakened estimates; however, fetuin-A has been shown to have high stability over a period of several years (36) , and the strong association that we observed among women indicates that a single measurement was sufficient. CT imaging, while an improvement over liver enzymes in the assessment of liver fat content, still has only moderate sensitivity and specificity compared with liver biopsy, the gold standard for determining liver fat content (37) ; therefore, the influence of liver fat on the association between fetuin-A and incident diabetes may have been underestimated. However, the invasiveness of liver biopsy precludes its use in large epidemiologic studies. Finally, small case numbers in stratified analyses may have limited our ability to detect differences in the association by NAFLD or other potential effect modifiers.
In conclusion, higher fetuin-A concentrations appear to be strongly associated with diabetes risk among women, with similar but more modest associations among men. Associations of fetuin-A with diabetes were minimally attenuated after adjustment for liver fat content, as assessed on CT scans. NAFLD did not modify associations of fetuin-A with diabetes in either sex. Future studies are needed to clarify discrepancies in sex-specific associations across studies and to investigate potential mechanisms through which fetuin-A might be related to the development of diabetes.
